These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1683277)

  • 1. [A double-blind study on the effect of dexetimide in the control of neuroleptic-induced extrapyramidal side-effects].
    Chen Y
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Aug; 24(4):197-9, 251. PubMed ID: 1683277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms.
    Chouinard G; Annable L; Mercier P; Turnier L
    Psychopharmacol Bull; 1987; 23(1):221-6. PubMed ID: 2885889
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical management of acute neuroleptic-induced extrapyramidal syndromes.
    Keepers GA; Casey DE
    Curr Psychiatr Ther; 1986; 23():139-57. PubMed ID: 2870879
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal].
    Ben Hadj Ali B; Dogui M; Ben Ammou S; Lôo H
    Encephale; 1995; 21(3):209-15. PubMed ID: 7649071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
    Cortese L; Caligiuri MP; Williams R; Schieldrop P; Manchanda R; Malla A; Harricharan R
    J Clin Psychopharmacol; 2008 Feb; 28(1):69-73. PubMed ID: 18204344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms.
    Fayen M; Goldman MB; Moulthrop MA; Luchins DJ
    Am J Psychiatry; 1988 Apr; 145(4):483-6. PubMed ID: 2894780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs.
    Kabes J; Sikora J; Pisvejc J; Hanzlicek L; Skondia V
    Int Pharmacopsychiatry; 1982; 17(3):185-92. PubMed ID: 6128331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical and legal implications of side effects from neuroleptic drugs. A round-table discussion.
    Cancro R; Davis JM; Klawans H; Tancredi L
    J Clin Psychiatry; 1981 Feb; 42(2):78-82. PubMed ID: 6109720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrapyramidal side effects: a historical perspective.
    Rifkin A
    J Clin Psychiatry; 1987 Sep; 48 Suppl():3-6. PubMed ID: 2887555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selegiline for neuroleptic-induced parkinsonism.
    Gewirtz GR; Sharif Z; Cadet JL; Sarti P; Gorman JM
    Pharmacopsychiatry; 1993 Jul; 26(4):128-9. PubMed ID: 7901857
    [No Abstract]   [Full Text] [Related]  

  • 12. A double-blind comparison of the efficacy of EX 10-029 and trihexyphenidyl hydrochloride in relieving drug-induced Parkinsonian symptoms.
    Freeman H; Mehta IS
    Curr Ther Res Clin Exp; 1972 Aug; 14(8):470-7. PubMed ID: 4629309
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics.
    Manos N; Lavrentiadis G; Gkiouzepas J
    J Clin Psychiatry; 1986 Mar; 47(3):114-6. PubMed ID: 2869027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism.
    Wirshing WC; Freidenberg DL; Cummings JL; Bartzokis G
    J Clin Psychopharmacol; 1989 Dec; 9(6):407-11. PubMed ID: 2574192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Side effects during long-term treatment with depot antipsychotic medication.
    Cookson JC
    Clin Neuropharmacol; 1991; 14 Suppl 2():S24-30; discussion S30-2. PubMed ID: 1751940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
    Lohr JB; Caligiuri MP
    J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inefficacy of propranolol in attenuation of drug-induced parkinsonian tremor.
    Metzer WS; Paige SR; Newton JE
    Mov Disord; 1993; 8(1):43-6. PubMed ID: 8093548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy.
    Manos N; Gkiouzepas J; Logothetis J
    Am J Psychiatry; 1981 Feb; 138(2):184-8. PubMed ID: 6109453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propranolol for tardive dyskinesia and extrapyramidal side effects (pseudoparkinsonism) from neuroleptics.
    Kulik FA; Wilbur R
    Psychopharmacol Bull; 1980 Jul; 16(3):18-9. PubMed ID: 6105690
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of lergotrile on schizophrenia & drug induced parkinsonism.
    Small JG; Kellams JJ; Milstein V; Klapper M; Lemberger L
    Commun Psychopharmacol; 1977; 1(5):461-7. PubMed ID: 23919
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.